NOTIFICATION

Addendum

The following communication, dated 1 October 2024, is being circulated at the request of the delegation of Brazil.

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Title:** Resolution - RDC n. 187, November 8th, 2017.

|  |  |
| --- | --- |
| **Reason for Addendum:** | |
| [ ] | Comment period changed - date: |
| [ ] | Notified measure adopted - date: |
| [ ] | Notified measure published - date: |
| [ ] | Notified measure enters into force - date: |
| [ ] | Text of final measure available from[[1]](#footnote-1): |
| [X] | Notified measure withdrawn or revoked - date: 24 September 2024  Relevant symbol if measure re-notified: |
| [ ] | Content or scope of notified measure changed and text available from1:  New deadline for comments (if applicable): |
| [ ] | Interpretive guidance issued and text available from1: |
| [ ] | Other: |

**Description:** Resolution - RDC n. 187, November 8th, 2017 - previously notified through G/TBT/N/BRA/758 - which establishes the minimum requirements for the registration of Hyperimmune Serum in order to guarantee the quality, safety and efficacy of these products, was revoked by Resolution 914, 19 September 2024.

The final text is available only in Portuguese and can be downloaded at:

<https://antigo.anvisa.gov.br/documents/10181/6873824/RDC_914_2024_.pdf/754dff2a-fbe5-4a89-81ad-476ea4b77ac3>

**\_\_\_\_\_\_\_\_\_\_**

1. This information can be provided by including a website address, a pdf attachment, or other information on where the text of the final/modified measure and/or interpretive guidance can be obtained. [↑](#footnote-ref-1)